Presence of Concurrent TP53 Mutations Is Necessary to Predict Poor Outcomes within the SMAD4 Mutated Subgroup of Metastatic Colorectal Cancer

SIMPLE SUMMARY: Prior studies have resulted in conflicting conclusions on the value of SMAD4 mutations as a prognostic biomarker in metastatic colorectal cancer. In a cohort study of 433 patients with metastatic colorectal cancer, we showed that the presence of a coexisting mutation in TP53 is neces...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chongkai, Sandhu, Jaideep, Tsao, Amber, Fakih, Marwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332822/
https://www.ncbi.nlm.nih.gov/pubmed/35892903
http://dx.doi.org/10.3390/cancers14153644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332822/
https://www.ncbi.nlm.nih.gov/pubmed/35892903
http://dx.doi.org/10.3390/cancers14153644

Ejemplares similares